Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Genetic Screens02:46

Genetic Screens

5.5K
Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing  genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
5.5K
Human Genetics01:28

Human Genetics

1.3K
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
1.3K
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

15.1K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
15.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Morbidity, Recurrence and Survival Following Pelvic Exenteration for Gynaecological Malignancies: A Retrospective, Single-Centre Study.

Journal of clinical medicine·2026
Same author

3D pentaculture model unveils malignant cell-driven macrophage polarization in high-grade serous ovarian cancer.

Nature communications·2026
Same author

Risk-Reducing Salpingectomy: An Emerging, Novel Ovarian Cancer Prevention Strategy.

BJOG : an international journal of obstetrics and gynaecology·2026
Same author

Evaluation of the Quality and Suitability of Self-Collected Vaginal and Urine Samples for Human Papillomavirus Testing: A Prospective Matched Study.

BJOG : an international journal of obstetrics and gynaecology·2026
Same author

Consent model for tumour genetic testing in ovarian cancer.

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology·2025
Same author

P-POSSUM Falls Short: Predicting Morbidity in Ovarian Cancer (OC) Cytoreductive Surgery.

Cancers·2025

Related Experiment Video

Updated: Dec 21, 2025

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.5K

Population-based Genetic Testing for Precision Prevention.

Olivia Evans1,2, Ranjit Manchanda3,2

  • 1Wolfson Institute of Preventative Medicine, Barts CRUK Cancer Centre, Queen Mary University of London, Charterhouse Square, London, United Kingdom.

Cancer Prevention Research (Philadelphia, Pa.)
|May 16, 2020
PubMed
Summary

Population-based genetic testing for cancer susceptibility genes (CSG) offers a more equitable approach than family history, enabling early risk reduction. Studies show it is feasible, cost-effective, and well-received, supporting a paradigm shift.

More Related Videos

Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform
09:30

Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform

Published on: August 17, 2022

3.4K
FISH for Pre-implantation Genetic Diagnosis
07:34

FISH for Pre-implantation Genetic Diagnosis

Published on: February 23, 2011

37.7K

Related Experiment Videos

Last Updated: Dec 21, 2025

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.5K
Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform
09:30

Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform

Published on: August 17, 2022

3.4K
FISH for Pre-implantation Genetic Diagnosis
07:34

FISH for Pre-implantation Genetic Diagnosis

Published on: February 23, 2011

37.7K

Area of Science:

  • Genetics
  • Oncology
  • Public Health

Background:

  • Current genetic testing for cancer susceptibility genes (CSG) relies on clinical criteria and family history, leading to inequality and underutilization.
  • This approach misses approximately 50% of CSG carriers, representing missed opportunities for precision prevention.
  • Early identification of CSG carriers allows for risk-reducing strategies in unaffected individuals to lower cancer risk.

Purpose of the Study:

  • To evaluate the feasibility, acceptability, and cost-effectiveness of population-based genetic testing (PGT) for CSGs.
  • To explore the potential of PGT to overcome limitations of current clinical criteria-based testing.
  • To inform the development of implementation strategies for wider PGT adoption.

Main Methods:

  • Review of existing studies on population-based BRCA testing in the Jewish population.
  • Analysis of emerging data on general population PGT.
  • Examination of risk prediction models incorporating genetic and nongenetic data for risk-adapted screening.

Main Results:

  • Population-based BRCA testing in the Jewish population is feasible, acceptable, cost-effective, and does not negatively impact psychologic well-being.
  • Emerging data suggest PGT is potentially cost-effective for panel testing of breast and ovarian CSGs.
  • Sophisticated risk models are being used for risk stratification and adapted screening.

Conclusions:

  • PGT offers a promising alternative to current methods for identifying individuals at high risk for hereditary cancers.
  • Implementation of PGT requires context-specific strategies and further research into its long-term impact and consequences.
  • A paradigm shift towards PGT could enhance precision prevention efforts and reduce cancer burden.